Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects With Relapsed and/or Refractory Multiple Myeloma (MM)

Trial Profile

Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects With Relapsed and/or Refractory Multiple Myeloma (MM)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs P-BCMA-101 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Poseida Therapeutics
  • Most Recent Events

    • 20 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 18 Sep 2017 Status changed from planning to not yet recruiting.
    • 21 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top